专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018075375A1 ANTI-O1 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗O1抗体及其用途
公开(公告)号：WO2018075375A1
公开(公告)日：2018-04-26
申请号：PCT/US2017/056725
申请日：2017-10-16
申请人： MEDIMMUNE, LLC , HUMABS BIOMED SA
发明人： WANG, Qun , STOVER, Charles K. , PENNINI, Meghan , CHANG, Chew-Shun , XIAO, Xiaodong , HILLIARD, Jamese , KAPLAN, Gilad , CORTI, Davide , CAMERONI, Elisabetta , BELTRAMELLO, Martina
IPC分类号： C07K16/12 , A61K39/395 , A61K39/40
摘要： The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae ). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae ) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae ) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.
摘要翻译：本披露提供了与肺炎克雷伯氏菌特异性结合并诱导克氏杆菌的调理素吞噬杀伤的结合蛋白（例如，其抗体或其抗原结合片段）（例如肺炎克雷伯氏菌）。本发明还提供了减少克雷伯氏菌属（例如肺炎克雷伯氏菌）或治疗或预防克雷伯氏菌属（例如肺炎克雷伯菌（Klebsiella pneumoniae）（包括将抗肺炎克雷伯氏菌O1结合蛋白（例如，抗体或其抗原结合片段））施用于受试者。

2. 发明申请

WO2018027124A8 ANTI-O2 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2018027124A8
公开(公告)日：2018-02-08
申请号：PCT/US2017/045480
申请日：2017-08-04
申请人： MEDIMMUNE, LLC , HUMABS BIOMED SA
发明人： WANG, Qun , STOVER, Charles, K. , PENNINI, Meghan , XIAO, Xiaodong , CORTI, Davide , CAMERONI, Elisabetta , BELTRAMELLO, Martina , KAPLAN, Gilad , DEMARCO, Anna
IPC分类号： A61K39/02 , A61K39/108 , A61K39/395 , A61K39/40 , A61K31/715 , C12P21/08
摘要： The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae 02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae ) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae ) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae ) infection in a subject comprising administering the Klebsiella pneumoniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

3. 发明申请

WO2017095744A1 METHOD FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA 审中-公开
标题翻译：预防或治疗医院感染的方法
公开(公告)号：WO2017095744A1
公开(公告)日：2017-06-08
申请号：PCT/US2016/063865
申请日：2016-11-28
申请人： MEDIMMUNE, LLC
发明人： JAFRI, Hasan , DIGIANDOMENICO, Anthony , MCCARTHY, Michael , YU, Xiang-Qing , STOVER, Charles, K. , BISHOP, Brian
IPC分类号： C07H21/04 , C12P21/08 , A61K39/00 , A61K39/104 , C07K16/00
CPC分类号： C07K16/1214 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/76
摘要： A method for preventing or treating nosocomial diseases, e.g., diseases caused by Pseudomonas aeruginosa , is provided. The method includes administering to a susceptible human a specified dose of a bispecific antibody that that specifically binds Pseudomonas aeruginosa Psl and PcrV.
摘要翻译：提供了用于预防或治疗医院疾病例如由铜绿假单胞菌引起的疾病的方法。该方法包括给易感人施用特异性结合铜绿假单胞菌Psl和PcrV的特定剂量的双特异性抗体。

4. 发明申请

WO2016036678A1 FORMULATIONS OF BISPECIFIC ANTIBODIES 审中-公开
标题翻译：双歧杆菌抗体制剂
公开(公告)号：WO2016036678A1
公开(公告)日：2016-03-10
申请号：PCT/US2015/047843
申请日：2015-09-01
申请人： MEDIMMUNE, LLC
发明人： CHOUDHARY, Sureshkumar , PARUPUDI, Arun
IPC分类号： A61K39/395
CPC分类号： C07K16/2809 , A61K39/39591 , C07K16/3007 , C07K2317/31
摘要： The present invention provides pharmaceutical formulations of bispecific antibodies, including bispecific antibodies comprising a first binding domain that suitably binds the CD3 T cell surface antigen and a second binding domain, which suitably binds carcinoembryonic antigen (CEA). The formulations are suitably designed for subcutaneous administration or injection. The present invention also provides methods of determining suitable buffers and excipients for use in protein formulations, particularly for antibody formulations.
摘要翻译：本发明提供双特异性抗体的药物制剂，包括双特异性抗体，其包含适当结合CD3T细胞表面抗原的第一结合结构域和适合结合癌胚抗原（CEA）的第二结合结构域。制剂适用于皮下给药或注射。本发明还提供了确定用于蛋白质制剂，特别是用于抗体制剂的合适的缓冲剂和赋形剂的方法。

5. 发明申请

WO2018027124A1 ANTI-O2 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗O2抗体及其用途
公开(公告)号：WO2018027124A1
公开(公告)日：2018-02-08
申请号：PCT/US2017/045480
申请日：2017-08-04
申请人： MEDIMMUNE, LLC , HUMABS, BIOMED, SA
发明人： WANG, Qun , STOVER, Charles, K. , PENNINI, Meghan , XIAO, Xiaodong , CORTI, Davide , CAMERONI, Elisabetta , BELTRAMELLO, Martina , KAPLAN, Gilad , DEMARCO, Anna
IPC分类号： A61K39/02 , A61K39/108 , A61K39/395 , A61K39/40 , A61K31/715 , C12P21/08
摘要： The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae 02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae ) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae ) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae ) infection in a subject comprising administering the Klebsiella pneumoniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.
摘要翻译：本披露提供了与肺炎克雷伯氏菌特异性结合并诱导调理吞噬杀死的结合蛋白（例如，其抗体或其抗原结合片段）克雷伯菌属（例如克雷伯菌属肺炎）和/或保护小鼠免于致死克雷伯氏菌挑战。本发明还提供了减少克雷伯氏菌属（例如肺炎克雷伯氏菌）或治疗或预防克雷伯氏菌属（例如肺炎克雷伯菌（Klebsiella pneumoniae）（包括将抗肺炎克雷伯氏菌O 2结合蛋白（例如，抗体或其抗原结合片段））施用于受试者。

6. 发明申请

WO2016144675A1 VACCINE DOSE AND USE THEREOF 审中-公开
标题翻译：疫苗剂量及其用途
公开(公告)号：WO2016144675A1
公开(公告)日：2016-09-15
申请号：PCT/US2016/020597
申请日：2016-03-03
申请人： MEDIMMUNE, LLC
发明人： ESSER, Mark, Thomas , VILLAFANA, Tonya, Luana , FALLOON, Judith , DUBOVSKY, Filip
IPC分类号： A61K39/00 , A61K39/12 , A61K39/155 , A61K39/39 , A61P31/14 , A61P37/04
CPC分类号： A61K39/12 , A61K2039/55566 , A61K2039/55572 , C12N2760/18534
摘要： Disclosed are methods of enhancing respiratory syncytial virus (RSV) immunity in a human subject. The methods encompass administering to a subject a single intramuscular dose of a composition comprising about 20 μg, about 50 μg, 80 μg or about 120 μg RSV soluble F protein. The composition further contains an adjuvant of glucopyranosyl lipid A (GLA) in a squalene-based stable emulsion. The RSV soluble F (sF) protein is amino acids 1-524 of RSV soluble F protein from human strain A2 lacking a transmembrane domain (SEQ ID NO: 1). In some embodiments the subject is human and is at least about 60 years old, or between at least about 60 years old and about 87 years old. In additional embodiments, the method of enhancing RSV immunity in the subject results in enhancing a Th1 biased cellular immune response in the subject, inducing neutralizing antibodies against RSV in the subject, reducing RSV viral titers in the subject, inducing an immune response to RSV in the subject, and/or preventing RSV infection in the subject.
摘要翻译：公开了在人类受试者中增强呼吸道合胞病毒（RSV）免疫的方法。所述方法包括对受试者施用包含约20μg，约50μg，80μg或约120μgRSV可溶性F蛋白的组合物的单次肌内剂量。该组合物还含有一种基于角鲨烯的稳定乳剂中的吡喃葡萄糖基脂质A（GLA）的佐剂。 RSV可溶性F（sF）蛋白是来自缺乏跨膜结构域（SEQ ID NO：1）的人类A2的RSV可溶性F蛋白的氨基酸1-524。在一些实施方案中，受试者是人，至少约60岁，或至少约60岁至约87岁。在另外的实施方案中，增强受试者RSV抗体的方法导致增加受试者中Th1偏向细胞免疫应答，诱导受试者中RSV抗体的中和抗体，减少受试者中的RSV病毒滴度，诱导针对RSV的免疫应答受试者和/或预防受试者的RSV感染。

7. 发明申请

WO2012141936A1 VARIANTS OF HUMAN GDNF 审中-公开
标题翻译：人类GDNF的变化
公开(公告)号：WO2012141936A1
公开(公告)日：2012-10-18
申请号：PCT/US2012/031927
申请日：2012-04-03
申请人： ELI LILLY AND COMPANY , LEUNG, Donmienne, Doen, Mun , LU, Jirong , MERCHANT, Kalpana, Mahesh , GHANEM, Mahmoud , O'BRYAN, Linda, Maureen , SMITH, Rosamund, Carol
发明人： LEUNG, Donmienne, Doen, Mun , LU, Jirong , MERCHANT, Kalpana, Mahesh , GHANEM, Mahmoud , O'BRYAN, Linda, Maureen , SMITH, Rosamund, Carol
IPC分类号： A61K38/18 , C07K14/475
CPC分类号： C07K14/47 , A61K38/00 , A61K38/185 , C07K14/475
摘要： The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use.
摘要翻译：本发明涉及人神经胶质细胞衍生的神经营养因子（GDNF）的新变体及其使用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式